Results 131 to 140 of about 5,144 (141)

Ixekizumab treatment patterns and healthcare utilization and costs for patients with psoriasis

Journal of Dermatological Treatment, 2021
Russel T Burge, Orin Goldblum, Mwangi J Murage   +2 more
exaly  

Ixekizumab May Improve Renal Function in Psoriasis

Healthcare, 2021
Luigi Bennardo, Emilio Russo
exaly  

Ixekizumab for the treatment of ankylosing spondylitis

Expert Review of Clinical Immunology, 2020
Jinxian Huang, Yung-Heng Lee
exaly  

The safety of ixekizumab in psoriasis drug therapy

Expert Opinion on Drug Safety, 2020
Luis Puig
exaly  

Improvements in psoriasis within different body regions vary over time following treatment with ixekizumab

Journal of Dermatological Treatment, 2018
Craig H Mallinckrodt
exaly  

Safety of ixekizumab in adult patients with plaque psoriasis, psoriatic arthritis and axial spondyloarthritis: data from 21 clinical trials.

Rheumatology, 2020
Mark C Genovese, Kim A. Papp, Gaia Gallo
exaly  

Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials

Lancet, The, 2015
Kristian Reich, Christopher Griffiths, Kim A. Papp   +2 more
exaly  

Ixekizumab treatment shows a neutral impact on cardiovascular parameters in patients with moderate-to-severe plaque psoriasis: Results from UNCOVER-1, UNCOVER-2, and UNCOVER-3

Journal of the American Academy of Dermatology, 2018
Alexander Egeberg, Jashin J. Wu, James A Solomon   +2 more
exaly  

Ixekizumab for the Treatment of Psoriasis: A Review of Phase III Trials

Dermatology and Therapy, 2016
Tina Bhutani, Mio Nakamura, John Koo
exaly  

Efficacy and safety of ixekizumab in patients with plaque psoriasis across different degrees of disease severity: results from UNCOVER-2 and UNCOVER-3

Journal of Dermatological Treatment, 2019
Yves Dutronc, Lajos Kemény, Carle Paul
exaly